Preliminary evaluation of anticonvulsant activity and neurotoxicity of some 1,4-substituted piperazine derivatives

Acta Poloniae Pharmaceutica - Drug Research

Volumn 66, Issue 5, 2009, Pages 571-578

  Marona, Henryk ^a   Gunia, Agnieszka ^a   Słoczyska, Karolina ^a   Rapacz, Anna ^a   Filipek, Barbara ^a   Cegła, Marek ^a   Opoka, Włodzimierz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

1,4 Piperazine derivatives; Anticonvulsant activity; Neurotoxicity

Indexed keywords

1 [(2,6 DIMETHYLPHENOXY) ACETYL] 4 (2 METHOXYPHENYL) PIPERAZINE; 1 [(2,6 DIMETHYLPHENOXY) ACETYL] 4 (2 PYRIMIDYL) PIPERAZINE; 1 [(4 CHLOR 3 METHYLPHENOXY) ACETYL] 4 (2 METHOXYPHENYL) PIPERAZINE; 1 [(4 CHLOR 3 METHYLPHENOXY) ACETYL] 4 (2 PYRIDYL) PIPERAZINE; 1 [2 (2,4,6 TRIMETHYLPHENOXY) ETHYL] 4 (2 FLUOROPHENYL) PIPERAZINE HYDROCHLORIDE; 1 [3 (2,6 DIMETHYLPHENOXY) PROPYL] 4 (2 FLUOROPHENYL) PIPERAZINE HYDROCHLORIDE; 1 [3 (2,6 DIMETHYLPHENOXY) PROPYL] 4 (2 HYDROXYETHYL) PIPERAZINE DIHYDROCHLORIDE; 1 [3 (2,6 DIMETHYLPHENOXY) PROPYL] 4 BENZYLPIPERAZINE DIHYDROCHLORIDE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; MOUSE; NEUROTOXICITY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; SEIZURE; SEIZURE THRESHOLD;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; ELECTROSHOCK; MALE; MICE; NEUROTOXICITY SYNDROMES; PENTYLENETETRAZOLE; PIPERAZINES; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70350500425     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Löscher W., Schmidt D.: Epilepsia 47, 1 (2006).
2. Bialer M., Johannessen S.I., Kupferberg H.J, Levy R.H., Perucca E, Tomson T.: Epilepsy Res. 73, 1 (2007).
3. Aldenkamp A.P.: Seizure 15, 219 (2006).
4. Vingerhoets G.: Seizure 15, 221 (2006).
5. Sander J. W.: Curr. Opin. Neurol. 16, 165 (2003).
6. Marona H., Waszkielewicz A.M., Szneler E.: Acta Pol. Pharm Drug Res. 62, 345 (2005).
7. Stȩpień K., Tomaszewski M., Czuczuwar S.J: Pharmacol. Rep. 57, 719 (2005).
8. Jastrzȩbska-Wiȩsek M., Czarnecki R., Marona H.: Acta Pol. Pharm Drug Res. 65, 591 (2008).
9. Marona H., Korona R., Szneler E.: Boll. Chim. Farmac. 143, 329 (2004).
10. Macia̧g D., Filipek B., Czekaj T., Marona H., Nowak G.: Pharmazie 58, 899 (2003).
11. Macia̧g D., Bednarski M., Filipek B., Pociecha T., Szkaradek N., Marona H.: Pharmazie 63, 480 (2008).
12. Fischer W.: Seizure 11, 285 (2002).
13. Marona H., Antkiewicz-Michaluk L.: Acta Pol. Pharm. Drug Res. 55, 487 (1998).
14. Swain A.P., Naegele S.K.: J. Am. Chem. Soc. 76, 509 (1954).
15. Stables J.P., Kupferberg H.J.: The NIH anticonvulsant drug development (ADD) program: preclinical anticonvulsant screening project. in Molecular and Cellular Targets for Antiepileptic Drugs. Avanzini G., Tanganelli P., Avoli M. Eds., John Libbey, London 1997.
16. Brown W.C., Schiffman D.O., Swinyard E.A., Goodman L.S.: J. Pharmacol. Exp. Ther. 107, 273 (1953).
17. Barton M.E., Klein B.D., Wolf H.H., White H.S.: Epilepsy Res. 47, 217 (2001).
18. Kaminski R.F., Livingood M.R., Rogawski M.A.: Epilepsia 45, 864 (2004).